Patrik Dahlen joins DxS
This article was originally published in Scrip
The UK personalised medicine company DxS has appointed Dr Patrik Dahlen non-executive director. Dr Dahlen was CEO of the cancer diagnostics company Dako from 2005-09. Before that, he served as CEO of the Danish biotech company Biolmage and president of life sciences and senior vice-president at PerkinElmer.
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.